Cell and Gene Outsourcing

  1. April 2026 — CDMO Opportunities And Threats Report 5/8/2026

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

  2. Removing Cost Barriers To Scalable AAV Manufacturing 5/7/2026

    Alternative AAV manufacturing approaches can dramatically reduce cost per dose, improve scalability, and increase yields across serotypes, enabling broader patient access to gene therapies.

  3. Improving LVV And AAV Yield Through Cargo Gene Silencing 5/7/2026

    Silencing cargo gene expression during LVV and AAV production improves cell health, reduces impurities, and significantly increases vector yield for cytotoxic and difficult‑to‑manufacture transgenes.

  4. Beyond Complexity. Beyond Challenges. Beyond Expectations. Advancing Genomic Medicines From Discovery To Commericalization 5/6/2026

    Integrated genomic medicine reduces risk and timelines, improving consistency across modalities from research through clinical and commercial stages.

  5. CRISPR Based Technologies: Integrated DNA Technologies And Aldevron, Your Partners For Comprehensive Genomic Medicine Workflows 5/6/2026

    Integrated CRISPR workflows unify editing tools, manufacturing, and regulatory support, reducing risk and complexity while speeding a consistent path from research to clinic.

  6. Realize The Full Potential Of Your RNA Therapeutics: Aldevron's Optimized 5' UTR Backbones 5/6/2026

    Reducing immunogenic RNA byproducts while preserving yield is key for mRNA manufacturing. Optimized transcription and capping streamline processing, cut costs, and enable scalable workflows.

  7. DasherGRP mRNA: Optimized Fluorescent Protein 5/6/2026

    Fluorescent mRNA reporters enable rapid visual confirmation of delivery and expression in mammalian cells, with bright signal, transient expression, and quantitative readouts.

  8. Nanoplasmid Vector Platform 5/6/2026

    Smaller vector backbones boost yield, expression, and transfection while lowering toxicity and regulatory risk, enabling efficient viral, non‑viral, and mRNA workflows from research to clinic.

     

  9. Enhancing Gene Editing Outcomes And Safety for Clinical Translation With Next Generation Vectors 5/6/2026

    Learn how streamlined vector backbones can improve efficiency, consistency, and expression durability when reliability matters most.

  10. Portfolio Optimization Strategic Consulting 5/5/2026

    For each prospective compound, we help you think through its clinical implications, safety parameters, and side effects to establish what will differentiate it in the current market landscape. With multiple drugs and limited funds, you need to choose the right products early. These best prospects will then generate cash and asset value to develop others.

    In partnership with Health Advances, we’ll help you decide which investments will get you to an early proof of concept, which assets to advance and which to hold back, and which assets have synergies with others, whether in production, use, or market position. By the end of it all, you’ll have an effective, fully optimized portfolio.